Abpro Holdings (ABPO) Non Operating Income (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Non Operating Income came in at -$95000.0 in Q1 2026, up 89.77% YoY from -$50059.6 in Q1 2025, and down 101.26% on a QoQ basis from $7.5 million in Q4 2025.
Abpro Holdings (ABPO) Non Operating Income (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Non Operating Income data on file, last reported at -$95000.0 in Q1 2026.
- Quarterly Non Operating Income rose 89.77% year-over-year to -$95000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 464.33% YoY) and the FY2025 annual result came in at $5.6 million, up 106.77% from the prior year.
- Non Operating Income eased to -$95000.0 in Q1 2026, from $7.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $7.5 million in Q4 2025 to a low of -$5.2 million in Q4 2023.
- A 5-year average of $703254.1 and a median of -$95000.0 in 2026 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1435.64% in 2025, down 623.0% in 2025.
- Tracing ABPO's Non Operating Income over 5 years: stood at $2.6 million in 2022, then tumbled by 300.1% to -$5.2 million in 2023, then soared by 89.06% to -$564000.0 in 2024, then jumped by 1435.64% to $7.5 million in 2025, then plunged by 101.26% to -$95000.0 in 2026.
- The last three Non Operating Income figures came in at -$95000.0 (Q1 2026), $7.5 million (Q4 2025), and -$321000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 235,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95,000.00 |
| Dec 31, 2025 | 7.53 Mn |
| Sep 30, 2025 | -321,000.00 |
| Jun 30, 2025 | -723,000.00 |
| Mar 31, 2025 | -929,000.00 |
| Dec 31, 2024 | -564,000.00 |
| Sep 30, 2024 | -162,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | 366,622.00 |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 3.29 Mn |
| Dec 31, 2022 | 2.58 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 243,932.00 |
| Mar 31, 2022 | -532,287.00 |